SCHEMBL26036705

SCHEMBL26036705

CN1c2ccc(N)cc2Sc2cc(OC3CCC3)ccc21

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SNCA P37840 4/20 0.66
▸ NOX1 Q9Y5S8 4/20 0.55
▸ MEN1 O00255 1/20 0.55
▸ ADRA2A P08913 1/20 0.55
▸ ADRA2B P18089 1/20 0.55
▸ ADRA2C P18825 1/20 0.55
▸ CHRM3 P20309 1/20 0.55
▸ SLC6A2 P23975 1/20 0.55
▸ HTR2C P28335 1/20 0.55
▸ SLC6A4 P31645 1/20 0.55
▸ DRD3 P35462 1/20 0.55
▸ HTR2B P41595 1/20 0.55
▸ KMT2A Q03164 1/20 0.55
▸ L3MBTL1 Q9Y468 1/20 0.55
▸ PARP10 Q53GL7 1/20 0.36
▸ CHEK1 O14757 1/20 0.35
▸ AURKA O14965 1/20 0.35
▸ DAPK3 O43293 1/20 0.35
▸ JAK2 O60674 1/20 0.35
▸ PRKD3 O94806 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9419165 0.79 NOX1 (0.82) SNCANOX1MEN1ADRA2AADRA2B
SCHEMBL29214097 0.73 NOX1 (0.77) SNCANOX1MEN1ADRA2AADRA2B
SCHEMBL628732 0.71 NOX1 (1.00) SNCANOX1MEN1ADRA2AADRA2B
SCHEMBL7389154 0.69 SNCA (0.81) SNCANOX1MEN1ADRA2AADRA2B
SCHEMBL30019459 0.69 MAPT (0.52) MEN1ADRA2CDRD3KMT2AL3MBTL1
SCHEMBL10187265 0.68 PARP10 (0.60) PARP10BTKTNK2ACACBMAOA
SCHEMBL21771119 0.67 SNCA (0.71) SNCAMEN1KMT2ALMNACYP2D6
SCHEMBL21771496 0.66 SNCA (0.50) SNCANOX1MEN1SLC6A2SLC6A4
SCHEMBL30019147 0.66 MAPT (0.52) MEN1ADRA2CDRD3KMT2AL3MBTL1
SCHEMBL14999402 0.66 CYP3A4 (0.50) SLC6A2SLC6A4PARP10IGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11707452-B2 Modulators of alpha-synuclein proteolysis and associated methods of use ARVINAS OPERATIONS, INC. (US) 2023-07-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11707452-B2 Modulators of alpha-synuclein proteolysis and associated methods of use UCHL1, ADRM1, CRBN SNCA 8/4885NOX1 2360/4885MEN1 3483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback